FDA Fills Top Drug and Vaccine Oversight Posts as Overton Nomination Advances

For most Americans, the FDA is a name attached to a stamp of approval. You see it on a pill bottle or a vaccine box and trust that someone, somewhere, checked the science before it reached you. That trust depends heavily on who sits in the agency's top decision-making chairs. This week, the Trump administration made four of those seating decisions permanent, and the choices offer a window into where the agency is headed.

On Tuesday, the administration confirmed that three officials who had been serving in acting roles will now hold their positions permanently. Michael Davis, a psychiatrist, becomes director of the Center for Drug Evaluation and Research, the division responsible for reviewing and approving prescription and over-the-counter medications. Karim Mikhail, previously an official at Merck, will lead the Center for Biologics Evaluation and Research, which oversees vaccines, gene therapies, and other biologic products. Bret Koplow, an attorney who has worked at the FDA since 2011, will run the Center for Tobacco Products. These announcements came from the Department of Health and Human Services and follow last month's nomination of Heidi Overton to serve as FDA commissioner.

A fourth appointment marks new territory for the agency. Jared Seehafer will become the FDA's first deputy commissioner for technology and artificial intelligence. He joined the agency as an adviser in 2025 after founding a life science software company and working in biotech investment advising. His new title did not exist before this administration created it, and that alone tells you something about where FDA leadership thinks the future of drug regulation is heading.

Why These Roles Matter So Much

Think of CDER and CBER as two of the busiest gatekeepers in American public health. Every new drug, from cancer treatments to blood pressure medications, has to pass through CDER's review process before it reaches a pharmacy shelf. CBER handles an equally critical, if narrower, portfolio: vaccines, blood products, and increasingly complex biologic therapies like gene and cell treatments. The people running these centers make decisions that ripple out to millions of patients, doctors, and insurers.

Davis's background as a psychiatrist is notable given CDER's broad scope, which includes psychiatric medications alongside virtually every other drug class regulated by the federal government. Mikhail's history at Merck, a major pharmaceutical company, will likely draw scrutiny from advocacy groups who watch closely for potential conflicts of interest when industry veterans move into regulatory roles overseeing the same sector they once worked in. That's not an accusation of wrongdoing. It's simply the kind of scrutiny that comes with the territory, and rightly so, given how much public health depends on regulators being seen as independent referees rather than former players on the field.

Koplow's elevation at the Center for Tobacco Products carries its own weight. Tobacco regulation touches on decades-long public health battles over nicotine addiction, youth vaping, and flavored products marketed in ways that critics say appeal to younger users. His 15 years inside the agency suggest continuity rather than disruption in that particular fight, though continuity isn't always the same as progress.

The creation of a deputy commissioner role focused specifically on artificial intelligence reflects a broader push already underway at the FDA. The agency has publicly stated it wants staff to use AI tools to speed up review processes, and it has moved to consolidate its data platforms to support that goal. Imagine a factory line that used to be inspected by hand, one item at a time, now getting outfitted with automated scanners that can flag problems faster. That's roughly the promise being sold here: faster reviews, quicker approvals, less bureaucratic drag on getting new treatments to patients who need them.

But speed and safety don't always move in the same direction. Faster review cycles can mean life-saving drugs reach patients sooner, which matters enormously to someone waiting on a new cancer therapy or a treatment for a rare disease. It can also mean less time for regulators to catch subtle safety signals buried in trial data, the kind of red flags that sometimes only emerge after careful, unhurried scrutiny. AI tools might help catch patterns humans would miss, or they might introduce new blind spots nobody has fully mapped yet. Seehafer's appointment puts someone with private-sector AI and biotech investment experience in charge of navigating that tension, and how he balances it will shape drug approvals for years.

These four appointments arrive alongside a much bigger personnel decision still working its way through the confirmation process. Heidi Overton's nomination to lead the entire FDA was announced in August, and her selection has already drawn attention over what STAT previously reported as competing interests ahead of her confirmation. The leadership team being assembled beneath her, now with these four roles permanently filled, will carry out whatever regulatory philosophy she and the administration settle on once she's confirmed.

What Comes Next

Watch for how quickly these new directors move on pending drug and biologic applications, and whether AI-assisted review tools start showing up in decision timelines that regulators publicize. Patient advocacy groups will likely keep close tabs on Mikhail's industry background, watching for any policy shifts that seem to favor pharmaceutical companies over independent safety review. Tobacco control advocates will watch Koplow just as closely, particularly around flavored vaping products that have drawn FDA warnings but, in some cases, remained on shelves anyway.

The broader question hanging over all of this is whether an agency built on decades of methodical, sometimes frustratingly slow review can adopt new technology without cutting corners that matter. Patients want faster access to treatments. They also want assurance that whatever reaches them has been genuinely vetted, not just algorithmically approved. Finding that balance will define this leadership team's legacy, whether that legacy is remembered as a genuine step forward for public health or a cautionary tale about moving too fast in the name of efficiency.